John D Roberts, MD

• Alexa Siddon
• Ariadna Forray
• Daniel Zelterman
• Jeanne Hendrickson
• Joe El-Khoury
• Lauren Hachmann Sansing
• Lesley Devine
• Raisa Balbuena-Merle

Anemia, Sickle Cell

Health Care Management

• Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapyCurtis SA, Raisa BM, Roberts JD, Hendrickson JE, Starrels J, Lesley D, Michelle D, Daniel Z, Brandow AM. Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy. Transfusion And Apheresis Science 2021, 61: 103304. PMID: 34782244, PMCID: PMC9838733, DOI: 10.1016/j.transci.2021.103304.
• Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndromeHolkova B, Shafer D, Yazbeck V, Dave S, Bose P, Tombes MB, Shrader E, Wan W, Bandyopadhyay D, Weir C, Collins EB, Garnett A, Kmieciak M, Roberts JD, Garcia-Manero G, Grant S. Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Leukemia & Lymphoma 2020, 62: 1187-1194. PMID: 33356689, PMCID: PMC8106643, DOI: 10.1080/10428194.2020.1861270.
• Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain ComplaintsCurtis SA, Brandow AM, DeVeaux M, Zeltermam D, Devine L, Roberts JD. Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints. Cannabis And Cannabinoid Research 2020, 5: 255-262. PMID: 32923662, PMCID: PMC7480712, DOI: 10.1089/can.2019.0036.
• Medical marijuana certification for patients with sickle cell disease: a report of a single center experienceCurtis SA, Lew D, Spodick J, Hendrickson JE, Minniti CP, Roberts JD. Medical marijuana certification for patients with sickle cell disease: a report of a single center experience. Blood Advances 2020, 4: 3814-3821. PMID: 32790846, PMCID: PMC7448584, DOI: 10.1182/bloodadvances.2020002325.
• Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis useKoch CD, Xu L, Curtis SA, Roberts JD, Bunch DR, El-Khoury JM. Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use. Clinica Chimica Acta 2020, 510: 515-521. PMID: 32795544, DOI: 10.1016/j.cca.2020.08.014.
• Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspectsKanter J, Smith WR, Desai PC, Treadwell M, Andemariam B, Little J, Nugent D, Claster S, Manwani DG, Baker J, Strouse JJ, Osunkwo I, Stewart RW, King A, Shook LM, Roberts JD, Lanzkron S. Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Advances 2020, 4: 3804-3813. PMID: 32785684, PMCID: PMC7448595, DOI: 10.1182/bloodadvances.2020001743.
• Utilization, financial outcomes and stakeholder perspectives of a re-organized adult sickle cell programRousseau R, Weisberg DF, Gorero J, Parwani V, Bozzo J, Kenyon K, Smith C, Cole J, Curtis S, Forray A, Roberts JD. Utilization, financial outcomes and stakeholder perspectives of a re-organized adult sickle cell program. PLOS ONE 2020, 15: e0236360. PMID: 32706825, PMCID: PMC7380627, DOI: 10.1371/journal.pone.0236360.
• Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain TypesCurtis S, Forray A, Hendrickson J, Roberts J. Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types. Blood 2019, 134: 1028. DOI: 10.1182/blood-2019-129106.
• Case Management Featuring Community Health Workers Reduces Inpatient Health Care Utilization in Adults with Sickle Cell DiseaseSmith W, Sop D, Johnson S, Lipato T, Ferlis M, Mcmanus C, Guy M, Hartigan S, Holt E, McHenry C, Roberts J. Case Management Featuring Community Health Workers Reduces Inpatient Health Care Utilization in Adults with Sickle Cell Disease. Blood 2019, 134: 2104. DOI: 10.1182/blood-2019-130441.
• Statewide Intervention to Improve Medical Care Services Utilization Patterns of Adults Living with Sickle Cell DiseaseRoberts J, Andemariam B, Bozzo J, Du C, Curtis S, Latham D, Cyr M, Magras L. Statewide Intervention to Improve Medical Care Services Utilization Patterns of Adults Living with Sickle Cell Disease. Blood 2019, 134: 517. DOI: 10.1182/blood-2019-124462.
• Inpatient pain management in sickle cell diseaseZassman SM, Zamora FJ, Roberts JD. Inpatient pain management in sickle cell disease. American Journal Of Health-System Pharmacy 2019, 76: 1965-1971. PMID: 31605120, DOI: 10.1093/ajhp/zxz228.
• Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell diseaseBalbuena‐Merle R, Curtis SA, Devine L, Gibb DR, Karafin MS, Luckey CJ, Tormey CA, Siddon AJ, Roberts JD, Hendrickson JE. Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease. Transfusion 2019, 59: 3219-3227. PMID: 31355970, PMCID: PMC7075520, DOI: 10.1111/trf.15463.
• Prescription Opioid Misuse Index in sickle cell patients: A brief questionnaire to assess at-risk for opioid abuse.Smith WR, McClish DK, Roberts JD, Kandalaft O, Dahman B, Knisely J, Levenson J, Roseff S, Aisiku IP. Prescription Opioid Misuse Index in sickle cell patients: A brief questionnaire to assess at-risk for opioid abuse. Journal Of Opioid Management 2019, 15: 323-331. PMID: 31637684, DOI: 10.5055/jom.2019.0517.
• Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell DiseaseCurtis S, Balbuena-Merle R, Devine L, Zelterman D, Roberts J, Dearborn-Tomazos J, Sansing L, Hendrickson J. Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell Disease. Blood 2018, 132: 1093. DOI: 10.1182/blood-2018-99-117504.
• Medical Marijuana for Sickle Cell Disease: Results of Two Years of Certification in an Adult Sickle Cell CenterCurtis S, Lew D, Spodick J, Roberts J. Medical Marijuana for Sickle Cell Disease: Results of Two Years of Certification in an Adult Sickle Cell Center. Blood 2018, 132: 858. DOI: 10.1182/blood-2018-99-118290.
• Medical Marijuana Certification for Patients with Sickle Cell Disease: A Survey Study of Patient's Use and PreferencesCurtis S, Spodick J, Lew D, Roberts J. Medical Marijuana Certification for Patients with Sickle Cell Disease: A Survey Study of Patient's Use and Preferences. Blood 2018, 132: 1094. DOI: 10.1182/blood-2018-99-118345.
• Marijuana Use in Adults Living with Sickle Cell DiseaseRoberts JD, Spodick J, Cole J, Bozzo J, Curtis S, Forray A. Marijuana Use in Adults Living with Sickle Cell Disease. Cannabis And Cannabinoid Research 2018, 3: 162-165. PMID: 30014039, PMCID: PMC6044416, DOI: 10.1089/can.2018.0001.
• A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell LymphomaYazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2018, 18: 569-575.e1. PMID: 30122201, DOI: 10.1016/j.clml.2018.05.023.
• Predictive Ability of Intermittent Daily Sickle Cell Pain Assessment: The PiSCES ProjectSmith WR, McClish DK, Levenson J, Aisiku I, Dahman B, Bovbjerg VE, Roseff S, Roberts J. Predictive Ability of Intermittent Daily Sickle Cell Pain Assessment: The PiSCES Project. Pain Medicine 2017, 19: 1972-1981. PMID: 29036363, PMCID: PMC6176749, DOI: 10.1093/pm/pnx214.
• Comorbidity, Pain, Utilization, and Psychosocial Outcomes in Older versus Younger Sickle Cell Adults: The PiSCES ProjectMcClish DK, Smith WR, Levenson JL, Aisiku IP, Roberts JD, Roseff SD, Bovbjerg VE. Comorbidity, Pain, Utilization, and Psychosocial Outcomes in Older versus Younger Sickle Cell Adults: The PiSCES Project. BioMed Research International 2017, 2017: 4070547. PMID: 28459058, PMCID: PMC5387810, DOI: 10.1155/2017/4070547.
• Marijuana use in adults with sickle cell diseaseForray A, Bozzo J, Cole J, Spodick J, Roberts J. Marijuana use in adults with sickle cell disease. Drug And Alcohol Dependence 2017, 171: e64-e65. DOI: 10.1016/j.drugalcdep.2016.08.187.
• A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphomaHolkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, Roberts JD, Shea TC, Grant S. A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leukemia & Lymphoma 2017, 58: 1349-1357. PMID: 28103725, PMCID: PMC5817887, DOI: 10.1080/10428194.2016.1276287.
• Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical TrialHimelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O’Connor T, Velasco MR, Weckstein D, O’Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 2017, 317: 48-58. PMID: 28030702, PMCID: PMC5321662, DOI: 10.1001/jama.2016.19425.
• Phase I study of pemetrexed with sorafenib in advanced solid tumorsPoklepovic A, Gordon S, Shafer DA, Roberts JD, Bose P, Geyer CE, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, Moran RG, Dent P. Phase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget 2016, 7: 42625-42638. PMID: 27213589, PMCID: PMC5173162, DOI: 10.18632/oncotarget.9434.
• A phase I study of indoximod in patients with advanced malignanciesSoliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. A phase I study of indoximod in patients with advanced malignancies. Oncotarget 2016, 7: 22928-22938. PMID: 27008709, PMCID: PMC5008412, DOI: 10.18632/oncotarget.8216.
• A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaHolkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research 2016, 22: 1067-1075. PMID: 26446942, PMCID: PMC4775365, DOI: 10.1158/1078-0432.ccr-15-1076.
• Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumorsWong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Annals Of Oncology 2015, 27: 318-323. PMID: 26598548, PMCID: PMC4722891, DOI: 10.1093/annonc/mdv537.
• Phase I study of pemetrexed and sorafenib in advanced solid tumors.Poklepovic A, Shafer D, Roberts J, Geyer C, Dent P, Moran R, Tombes M, Shrader E, Strickler K, Wan W. Phase I study of pemetrexed and sorafenib in advanced solid tumors. Journal Of Clinical Oncology 2015, 33: 2586-2586. DOI: 10.1200/jco.2015.33.15_suppl.2586.
• CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.Himelstein A, Qin R, Novotny P, Seisler D, Khatcheressian J, Roberts J, Grubbs S, O'Connor T, Weckstein D, Loprinzi C, Shapiro C. CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal Of Clinical Oncology 2015, 33: 9501-9501. DOI: 10.1200/jco.2015.33.15_suppl.9501.
• Daily home opioid use in adults with sickle cell disease: The PiSCES project.Smith WR, McClish DK, Dahman BA, Levenson JL, Aisiku IP, de A Citero V, Bovbjerg VE, Roberts JD, Penberthy LT, Roseff SD. Daily home opioid use in adults with sickle cell disease: The PiSCES project. Journal Of Opioid Management 2015, 11: 243-53. PMID: 25985809, DOI: 10.5055/jom.2015.0273.
• Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated ResultsHolkova B, Kmieciak M, Bose P, Ma S, Kimball A, Tombes M, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Singh A, Dean A, Conine S, Sankala H, Roberts J, Shea T, Grant S. Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results. Blood 2014, 124: 3050. DOI: 10.1182/blood.v124.21.3050.3050.
• Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell NeoplasmsHolkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S. Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. Clinical Cancer Research 2014, 20: 5652-5662. PMID: 25248382, PMCID: PMC4233160, DOI: 10.1158/1078-0432.ccr-14-0805.
• Erratum to: Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcomaPoklepovic A, Youssefian L, Winning M, Birdsell C, Crosby N, Ramakrishnan V, Ernstoff M, Roberts J. Erratum to: Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Investigational New Drugs 2013, 31: 1095-1095. DOI: 10.1007/s10637-013-9997-9.
• A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S. A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2. Clinical Cancer Research 2013, 19: 1873-1883. PMID: 23515411, PMCID: PMC3618599, DOI: 10.1158/1078-0432.ccr-12-2926.
• Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcomaPoklepovic A, Youseffian L, Winning M, Birdsell CA, Crosby NA, Ramakrishnan V, Ernstoff MS, Roberts JD. Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Investigational New Drugs 2013, 31: 937-942. PMID: 23315028, PMCID: PMC3844155, DOI: 10.1007/s10637-012-9913-8.
• Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year UpdateHolkova B, Bose P, Tombes M, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Sankala H, Kmieciak M, Roberts J, Garcia-Manero G, Grant S. Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update. Blood 2012, 120: 3588. DOI: 10.1182/blood.v120.21.3588.3588.
• Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell LymphomaHolkova B, Shea T, Bose P, Tombes M, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Sankala H, Kmieciak M, Roberts J, Grant S. Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma. Blood 2012, 120: 1794. DOI: 10.1182/blood.v120.21.1794.1794.
• Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.Holkova B, Perkins E, Bose P, Sullivan D, Baz R, Tombes M, Shrader E, Ramakrishnan V, Wan W, Sankala H, Kmieciak M, Roberts J, Grant S. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib. Blood 2012, 120: 2959. DOI: 10.1182/blood.v120.21.2959.2959.
• Pain and disease severity relate to long versus short-acting opioid use in adults with sickle cell disease: the PiSCES projectSmith W, McClish D, Dahman B, Levenson J, Aisiku I, Citero V, Bovbjerg V, Roberts J, Penberthy L, Roseff S, Scherer M, Weaver M. Pain and disease severity relate to long versus short-acting opioid use in adults with sickle cell disease: the PiSCES project. Journal Of Pain 2012, 13: s15. DOI: 10.1016/j.jpain.2012.01.067.
• Home opioid use in sickle cell disease and relationship to pain and psychosocial variables: the PiSCES projectSmith W, McClish D, Dahman B, Levenson J, Aisiku I, Citero V, Bovbjerg V, Roberts J, Penberthy L, Roseff S, Scherer M, Weaver M. Home opioid use in sickle cell disease and relationship to pain and psychosocial variables: the PiSCES project. Journal Of Pain 2012, 13: s13. DOI: 10.1016/j.jpain.2012.01.060.
• Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignanciesBose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant S. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemotherapy And Pharmacology 2012, 69: 1657-1667. PMID: 22349810, PMCID: PMC3365614, DOI: 10.1007/s00280-012-1839-5.
• Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast CrisisHolkova B, Tombes M, Shrader E, Cooke S, Wan W, Sankala H, Kmieciak M, Roberts J, Garcia-Manero G, Grant S. Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis. Blood 2011, 118: 2598. DOI: 10.1182/blood.v118.21.2598.2598.
• A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple MyelomaHolkova B, Badros A, Geller R, Voorhees P, Zingone A, Korde N, Lin H, Tombes M, Shrader E, Sankala H, Kmieciak M, Roberts J, Sullivan D, Landgren O, Grant S. A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma. Blood 2011, 118: 2931. DOI: 10.1182/blood.v118.21.2931.2931.
• A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell LymphomaHolkova B, Perkins E, Sokol L, Richards K, Parekh S, Elstrom R, Badros A, Espinoza-Delgado I, Schell M, Kimball A, Tombes M, Shrader E, Sankala H, Coppola D, Kmieciak M, Sullivan D, Roberts J, Grant S. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma. Blood 2011, 118: 779. DOI: 10.1182/blood.v118.21.779.779.
• Phase II Trials Powered to Detect Tumor SubtypesRoberts JD, Ramakrishnan V. Phase II Trials Powered to Detect Tumor Subtypes. Clinical Cancer Research 2011, 17: 5538-5545. PMID: 21737510, DOI: 10.1158/1078-0432.ccr-10-2466.
• Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell NeoplasmsHolkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts JD, Grant S. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms. Clinical Cancer Research 2011, 17: 3388-3397. PMID: 21447728, PMCID: PMC3096752, DOI: 10.1158/1078-0432.ccr-10-2876.
• Do African American Men Have Lower Survival From Prostate Cancer Compared With White Men? A Meta-analysisSridhar G, Masho SW, Adera T, Ramakrishnan V, Roberts JD. Do African American Men Have Lower Survival From Prostate Cancer Compared With White Men? A Meta-analysis. American Journal Of Men's Health 2010, 4: 189-206. PMID: 20483872, DOI: 10.1177/1557988309353934.
• A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumorsDickson MA, Rathkopf DE, Carvajal RD, Grant S, Roberts JD, Reid JM, Ames MM, McGovern RM, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK. A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Investigational New Drugs 2010, 29: 1004-1012. PMID: 20461440, PMCID: PMC3545439, DOI: 10.1007/s10637-010-9447-x.
• Association between family history of cancers and risk of prostate cancerSridhar G, Masho S, Adera T, Ramakrishnan V, Roberts J. Association between family history of cancers and risk of prostate cancer. Journal Of Men's Health 2010, 7: 45-54. DOI: 10.1016/j.jomh.2009.10.006.
• Pain site frequency and location in sickle cell disease: The PiSCES projectMcClish DK, Smith WR, Dahman BA, Levenson JL, Roberts JD, Penberthy LT, Aisiku IP, Roseff SD, Bovbjerg VE. Pain site frequency and location in sickle cell disease: The PiSCES project. Pain 2009, 145: 246-251. PMID: 19631468, PMCID: PMC2771372, DOI: 10.1016/j.pain.2009.06.029.
• The relationship between taste, olfaction, and nutrition in the cancer population.Farmer MN, Raddin RS, Roberts JD. The relationship between taste, olfaction, and nutrition in the cancer population. The Journal Of Supportive Oncology 2009, 7: 70-2. PMID: 19408461.
• Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumorsPavlick AC, Wu J, Roberts J, Rosenthal MA, Hamilton A, Wadler S, Farrell K, Carr M, Fry D, Murgo AJ, Oratz R, Hochster H, Liebes L, Muggia F. Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemotherapy And Pharmacology 2009, 64: 803. PMID: 19221754, PMCID: PMC3901370, DOI: 10.1007/s00280-009-0931-y.
• Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.Grant S, Sullivan D, Roodman D, Stuart R, Perkins E, Kolla S, Ramakrishnan V, Wright J, Colevas A, Tombes M, Roberts J. Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms. Blood 2008, 112: 1573. DOI: 10.1182/blood.v112.11.1573.1573.
• Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)Grant S, Kolla S, Sirulnik L, Shapiro G, Supko J, Cooper B, Perkins E, Ramakrishnan V, Espinoza-Delgado I, Tombes M, Roberts J. Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2). Blood 2008, 112: 2986. DOI: 10.1182/blood.v112.11.2986.2986.
• Comparisons of High Versus Low Emergency Department Utilizers in Sickle Cell DiseaseAisiku IP, Smith WR, McClish DK, Levenson JL, Penberthy LT, Roseff SD, Bovbjerg VE, Roberts JD. Comparisons of High Versus Low Emergency Department Utilizers in Sickle Cell Disease. Annals Of Emergency Medicine 2008, 53: 587-593. PMID: 18926599, DOI: 10.1016/j.annemergmed.2008.07.050.
• Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 ActivationZhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, Roberts JD, Fisher PB, Grant S, Dent P. Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation. Clinical Cancer Research 2008, 14: 5385-5399. PMID: 18765530, PMCID: PMC2561272, DOI: 10.1158/1078-0432.ccr-08-0469.
• High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD, Cancer and Leukemia Group B (CALGB).. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 2008, 111:5371-9.
• Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivoHamed H, Hawkins W, Mitchell C, Gilfor D, Zhang G, Pei XY, Dai Y, Hagan MP, Roberts JD, Yacoub A, Grant S, Dent P. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. Molecular Cancer Therapeutics 2008, 7: 616-629. PMID: 18347148, DOI: 10.1158/1535-7163.mct-07-2376.
• Daily assessment of pain in adults with sickle cell disease.Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts JD, Dahman B, Aisiku IP, Levenson JL, Roseff SD. Daily assessment of pain in adults with sickle cell disease. Annals Of Internal Medicine 2008, 148: 94-101. PMID: 18195334, DOI: 10.7326/0003-4819-148-2-200801150-00004.
• Depression and Anxiety in Adults With Sickle Cell Disease: The PiSCES ProjectLevenson JL, McClish DK, Dahman BA, Bovbjerg VE, de A. Citero V, Penberthy LT, Aisiku IP, Roberts JD, Roseff SD, Smith WR. Depression and Anxiety in Adults With Sickle Cell Disease: The PiSCES Project. Psychosomatic Medicine 2007, 70: 192-196. PMID: 18158366, DOI: 10.1097/psy.0b013e31815ff5c5.
• Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cellsMitchell C, Park MA, Zhang G, Yacoub A, Curiel DT, Fisher PB, Roberts JD, Grant S, Dent P. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Molecular Cancer Therapeutics 2007, 6: 3101-3112. PMID: 18065490, DOI: 10.1158/1535-7163.mct-07-0561.
• Patient satisfaction in specialized versus nonspecialized adult sickle cell care centers: the PiSCES study.Aisiku IP, Penberthy LT, Smith WR, Bovbjerg VE, McClish DK, Levenson JL, Roberts JD, Roseff SD. Patient satisfaction in specialized versus nonspecialized adult sickle cell care centers: the PiSCES study. Journal Of The National Medical Association 2007, 99: 886-90. PMID: 17722665, PMCID: PMC2574305.
• Low-Dose BBR3610 Toxicity in Colon Cancer Cells Is p53-Independent and Enhanced by Inhibition of Epidermal Growth Factor Receptor (ERBB1)-Phosphatidyl Inositol 3 Kinase SignalingMitchell C, Kabolizadeh P, Ryan J, Roberts JD, Yacoub A, Curiel DT, Fisher PB, Hagan MP, Farrell NP, Grant S, Dent P. Low-Dose BBR3610 Toxicity in Colon Cancer Cells Is p53-Independent and Enhanced by Inhibition of Epidermal Growth Factor Receptor (ERBB1)-Phosphatidyl Inositol 3 Kinase Signaling. Molecular Pharmacology 2007, 72: 704-714. PMID: 17578896, DOI: 10.1124/mol.107.038406.
• Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor TreatmentYacoub A, Hawkins W, Hanna D, Young H, Park MA, Grant M, Roberts JD, Curiel DT, Fisher PB, Valerie K, Grant S, Hagan MP, Dent P. Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment. Molecular Pharmacology 2006, 71: 259-275. PMID: 17050804, DOI: 10.1124/mol.106.031153.
• Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) LymphomaRoberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S. Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma. Clinical Cancer Research 2006, 12: 5809-5816. PMID: 17020988, DOI: 10.1158/1078-0432.ccr-05-2730.
• E2F1 amplication and genetic heterogeneity in melanoma.Roberts JD. E2F1 amplication and genetic heterogeneity in melanoma. Cancer Biology & Therapy 2006, 5: 691-2. PMID: 16775429, DOI: 10.4161/cbt.5.6.2926.
• Gender Differences in Pain and Healthcare Utilization for Adult Sickle Cell Patients: The PiSCES ProjectMcClish DK, Levenson JL, Penberthy LT, Roseff SD, Bovbjerg VE, Roberts JD, Aisiku IP, Smith WR. Gender Differences in Pain and Healthcare Utilization for Adult Sickle Cell Patients: The PiSCES Project. Journal Of Women's Health 2006, 15: 146-154. PMID: 16536678, DOI: 10.1089/jwh.2006.15.146.
• Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced MelanomaRoberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG. Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma. Journal Of Immunotherapy 2006, 29: 95-101. PMID: 16365605, DOI: 10.1097/01.cji.0000195295.74104.ad.
• Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphineRoberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. European Journal Of Pharmacology 2005, 530: 54-58. PMID: 16375890, DOI: 10.1016/j.ejphar.2005.11.036.
• Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies.Grant S, Karp J, Koc O, Cooper B, Luger S, Figg W, Egorin M, Druker B, Jacobberger J, Ramakrishnan V, Perkins E, Colevas A, Roberts J. Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies. Blood 2005, 106: 1102. DOI: 10.1182/blood.v106.11.1102.1102.
• Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.Grant S, Sullivan D, Roodman D, Stuart R, Perkins E, Ramakrishnan V, Wright J, Colevas A, Roberts J. Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms. Blood 2005, 106: 3338. DOI: 10.1182/blood.v106.11.3338.3338.
• Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor re-growthHawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, Dai Y, Dawson K, Ramakrishnan V, Roberts JD, Yacoub A, Grant S, Dent P. Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor re-growth. Cancer Biology & Therapy 2005, 4: 1275-1284. PMID: 16319524, DOI: 10.4161/cbt.4.11.2286.
• Health related quality of life in sickle cell patients: The PiSCES projectMcClish DK, Penberthy LT, Bovbjerg VE, Roberts JD, Aisiku IP, Levenson JL, Roseff SD, Smith WR. Health related quality of life in sickle cell patients: The PiSCES project. Health And Quality Of Life Outcomes 2005, 3: 50. PMID: 16129027, PMCID: PMC1253526, DOI: 10.1186/1477-7525-3-50.
• Understanding pain and improving management of sickle cell disease: the PiSCES study.Smith WR, Bovbjerg VE, Penberthy LT, McClish DK, Levenson JL, Roberts JD, Gil K, Roseff SD, Aisiku IP. Understanding pain and improving management of sickle cell disease: the PiSCES study. Journal Of The National Medical Association 2005, 97: 183-93. PMID: 15712781, PMCID: PMC2568749.
• Use of an implantable drug delivery system for refractory chronic sickle cell painSmith TJ, Coyne PJ, Smith WR, Roberts JD, Smith V. Use of an implantable drug delivery system for refractory chronic sickle cell pain. American Journal Of Hematology 2005, 78: 153-154. PMID: 15682408, DOI: 10.1002/ajh.20252.
• RTOG 97-06: Initial report of a Phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapyHagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU. RTOG 97-06: Initial report of a Phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 2003, 57: 665-672. PMID: 14529770, DOI: 10.1016/s0360-3016(03)00718-1.
• Phase I studies of weekly administration of cytotoxic agents: Implications of a mathematical modelMcClish DK, Roberts JD. Phase I studies of weekly administration of cytotoxic agents: Implications of a mathematical model. Investigational New Drugs 2003, 21: 299-308. PMID: 14578680, DOI: 10.1023/a:1025464510639.
• The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapyGrant S, Roberts JD. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resistance Updates 2003, 6: 15-26. PMID: 12654284, DOI: 10.1016/s1368-7646(02)00141-3.
• Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial.Cushman M, Costantino JP, Bovill EG, Wickerham DL, Buckley L, Roberts JD, Krag DN. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. British Journal Of Haematology 2003, 120: 109-16. PMID: 12492585, DOI: 10.1046/j.1365-2141.2003.03976.x.
• Phase I Study of Bryostatin-1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's LymphomaRoberts JD, Smith MR, Feldman EJ, Cragg L, Grant S. Phase I Study of Bryostatin-1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2002, 3: 184-188. PMID: 12521398, DOI: 10.3816/clm.2002.n.025.
• Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.Cragg LH, Andreeff M, Feldman E, Roberts J, Murgo A, Winning M, Tombes MB, Roboz G, Kramer L, Grant S. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia. Clinical Cancer Research 2002, 8: 2123-33. PMID: 12114412.
• Higher doses of mitoxantrone among men with hormone‐refractory prostate carcinomaLevine EG, Halabi S, Roberts JD, Kaplan EB, Rago R, Atkins JN, Vogelzang NJ. Higher doses of mitoxantrone among men with hormone‐refractory prostate carcinoma. Cancer 2002, 94: 665-672. PMID: 11857298, DOI: 10.1002/cncr.10217.
• RTOG 9706: initial report of a phase I/II trial of bladder-conservation employing TURB, accelerated irradiation sensitized with Cisplatin followed by adjuvant MCV chemotherapyHagan M, Winter K, Kaufman D, Shipley W, Heney N, Toonkel L, Jones C, Roberts J. RTOG 9706: initial report of a phase I/II trial of bladder-conservation employing TURB, accelerated irradiation sensitized with Cisplatin followed by adjuvant MCV chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 2001, 51: 14. DOI: 10.1016/s0360-3016(01)01849-1.
• Novel Approaches to Polynuclear Platinum Pro-Drugs. Selective Release of Cytotoxic Platinum−Spermidine Species through Hydrolytic Cleavage of CarbamatesHegmans A, Qu Y, Kelland L, Roberts J, Farrell N. Novel Approaches to Polynuclear Platinum Pro-Drugs. Selective Release of Cytotoxic Platinum−Spermidine Species through Hydrolytic Cleavage of Carbamates. Inorganic Chemistry 2001, 40: 6108-6114. PMID: 11703107, DOI: 10.1021/ic010509a.
• Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trialBear H, Roberts J, Cornell D, Tombes M, Kyle B. Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial. Cancer Immunology, Immunotherapy 2001, 50: 269-274. PMID: 11499810, DOI: 10.1007/s002620100199.
• A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics.Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, Roberts JD, Shaw EG, Pearlman AD, Venitz J, Dusenbery KE, Abraham DJ, Gerber MJ. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. International Journal Of Radiation Oncology, Biology, Physics 2001, 49: 1133-9. PMID: 11240256, DOI: 10.1016/s0360-3016(00)01532-7.
• Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect.Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD, Krag DN. Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. Arteriosclerosis, Thrombosis, And Vascular Biology 2001, 21: 255-61. PMID: 11156862, DOI: 10.1161/01.atv.21.2.255.
• Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer.Hillner BE, Roberts JD. Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer. Journal Of The National Cancer Institute 2000, 92: 1704-6. PMID: 11058606, DOI: 10.1093/jnci/92.21.1704.
• Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW, Shibata S, Spicer D, Bissett D, Pithavala YK, Collier MA, Paradiso LJ, Roberts JD. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clinical Cancer Research 2000, 6: 2677-84. PMID: 10914709.
• Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeksRoberts J, Shibata S, Spicer D, McLeod H, Tombes M, Kyle B, Carroll M, Sheedy B, Collier M, Pithavala Y, Paradiso L, Clendeninn N. Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemotherapy And Pharmacology 2000, 45: 423-427. PMID: 10803927, DOI: 10.1007/s002800051012.
• A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.Huan SD, Natale RB, Stewart DJ, Sartiano GP, Stella PJ, Roberts JD, Symes AL, Finizio M. A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2000, 6: 1333-6. PMID: 10778959.
• Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluationRoberts J, Poplin E, Tombes M, Kyle B, Spicer D, Grant S, Synold T, Moran R. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. Cancer Chemotherapy And Pharmacology 2000, 45: 103-110. PMID: 10663624, DOI: 10.1007/s002800050017.
• Cellular pharmacology of polynuclear platinum anti-cancer agentsRoberts J, Peroutka J, Farrell N. Cellular pharmacology of polynuclear platinum anti-cancer agents. Journal Of Inorganic Biochemistry 1999, 77: 51-57. PMID: 10626354, DOI: 10.1016/s0162-0134(99)00147-6.
• Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell linesRoberts J, Peroutka J, Beggiolin G, Manzotti C, Piazzoni L, Farrell N. Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines. Journal Of Inorganic Biochemistry 1999, 77: 47-50. PMID: 10626353, DOI: 10.1016/s0162-0134(99)00137-3.
• High-performance liquid chromatographic method for determination of vanillin and vanillic acid in human plasma, red blood cells and urine.Farthing D, Sica D, Abernathy C, Fakhry I, Roberts JD, Abraham DJ, Swerdlow P. High-performance liquid chromatographic method for determination of vanillin and vanillic acid in human plasma, red blood cells and urine. Journal Of Chromatography. B, Biomedical Sciences And Applications 1999, 726: 303-7. PMID: 10348200, DOI: 10.1016/s0378-4347(99)00031-6.
• Leucovorin, 5-fluorouracil, and gemcitabine: A phase I studyPoplin E, Roberts J, Tombs M, Grant S, Rubin E. Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study. Investigational New Drugs 1999, 17: 57-61. PMID: 10555123, DOI: 10.1023/a:1006239200772.
• Chemistry and Biology of Multifunctional DNA Binding AgentsFarrell N, Qu Y, Roberts J. Chemistry and Biology of Multifunctional DNA Binding Agents. 1999, 99-115. DOI: 10.1007/978-3-662-03815-4_4.
• Phase Ib trial of bryostatin 1 in patients with refractory malignancies.Grant S, Roberts J, Poplin E, Tombes MB, Kyle B, Welch D, Carr M, Bear HD. Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clinical Cancer Research 1998, 4: 611-8. PMID: 9533528.
• Modification of Platinum(II) Antitumor Complexes with Sulfur Ligands. 2. Reactivity and Nucleotide Binding Properties of Cationic Complexes of the Types [PtCl(diamine)(L)]NO3 and [{PtCl(diamine)}2(L-L)](NO3)2 (L = Monofunctional Thiourea Derivative; L-L = Bifunctional Thiourea Derivative) in Relation to Their CytotoxicityBierbach U, Roberts J, Farrell N. Modification of Platinum(II) Antitumor Complexes with Sulfur Ligands. 2. Reactivity and Nucleotide Binding Properties of Cationic Complexes of the Types [PtCl(diamine)(L)]NO3 and [{PtCl(diamine)}2(L-L)](NO3)2 (L = Monofunctional Thiourea Derivative; L-L = Bifunctional Thiourea Derivative) in Relation to Their Cytotoxicity. Inorganic Chemistry 1998, 37: 717-723. DOI: 10.1021/ic970421q.
• Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administrationBear H, McFadden A, Kostuchenko P, Lipshy K, Hamad G, Turner A, Roberts J, Carr M, Carr S, Grant S. Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration. Anti-Cancer Drugs 1996, 7: 299-306. PMID: 8792004, DOI: 10.1097/00001813-199605000-00010.
• Oxidative Addition of the Dithiobis(formamidinium) Cation to Platinum(II) Chloro Am(m)ine Compounds: Studies on Structure, Spectroscopic Properties, Reactivity, and Cytotoxicity of a New Class of Platinum(IV) Complexes Exhibiting S-Thiourea CoordinationBierbach U, Hambley TW, Roberts JD, Farrell N. Oxidative Addition of the Dithiobis(formamidinium) Cation to Platinum(II) Chloro Am(m)ine Compounds: Studies on Structure, Spectroscopic Properties, Reactivity, and Cytotoxicity of a New Class of Platinum(IV) Complexes Exhibiting S-Thiourea Coordination. Inorganic Chemistry 1996, 35: 4865-4872. PMID: 11666686, DOI: 10.1021/ic960314g.
• Increased Systemic, but Not Regional, Neopterin Production Following Intraperitoneral Administration of Interleukin-2 and Lack of Effect of Pterins upon the Lymphokine-Activated Killer Cell PhenomenonRoberts J, Bigelow J, Moore A, Belinson J, Stewart J, Hacker M. Increased Systemic, but Not Regional, Neopterin Production Following Intraperitoneral Administration of Interleukin-2 and Lack of Effect of Pterins upon the Lymphokine-Activated Killer Cell Phenomenon. Journal Of Immunotherapy 1994, 15: 53-58. PMID: 8110731, DOI: 10.1097/00002371-199401000-00007.
• Nitric Oxide Modulates Lymphocyte Proliferation But Not Secretion of IL-2Huot AE, Moore AL, Roberts JD, Hacker MP. Nitric Oxide Modulates Lymphocyte Proliferation But Not Secretion of IL-2. Immunological Investigations 1993, 22: 319-327. PMID: 7689536, DOI: 10.3109/08820139309063411.
• Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action.Farrell N, Kelland LR, Roberts JD, Van Beusichem M. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Research 1992, 52: 5065-72. PMID: 1516063.
• A phase i clinical trial of didemnin BStewart J, Low J, Roberts J, Blow A. A phase i clinical trial of didemnin B. Cancer 1991, 68: 2550-2554. PMID: 1933801, DOI: 10.1002/1097-0142(19911215)68:12<2550::aid-cncr2820681203>3.0.co;2-q.
• Activation of the trans geometry in platinum antitumor complexes.van Beusichem M, Fontes A, Roberts J, Kelland L, Farrell N. Activation of the trans geometry in platinum antitumor complexes. Journal Of Inorganic Biochemistry 1991, 43: 602. DOI: 10.1016/0162-0134(91)84573-r.
• Effect of obesity on plasma insulin-like growth factor-I in cancer patients.Colletti RB, Copeland KC, Devlin JT, Roberts JD, McAuliffe TL. Effect of obesity on plasma insulin-like growth factor-I in cancer patients. International Journal Of Obesity 1991, 15: 523-7. PMID: 1938095.
• Shikimic acid complexes of platinum. Preparation, reactivity, and antitumor activity of (R,R-1,2-diaminocyclohexane) bis(shikimato)platinum(II). Evidence for a novel rearrangement involving platinum—carbon bond formationFarrell N, Roberts J, Hacker M, Farrell N, Roberts J, Hacker M. Shikimic acid complexes of platinum. Preparation, reactivity, and antitumor activity of (R,R-1,2-diaminocyclohexane) bis(shikimato)platinum(II). Evidence for a novel rearrangement involving platinum—carbon bond formation. Journal Of Inorganic Biochemistry 1991, 42: 237-246. PMID: 1880505, DOI: 10.1016/0162-0134(91)84038-b.
• Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Research 1990, 50: 6302-10. PMID: 2205379.
• Chemistry, cytotoxicity, and DNA-binding of bis-platinum complexesKraker A, Elliot W, VanHouten B, Farrell N, Hoeschele J, Roberts J. Chemistry, cytotoxicity, and DNA-binding of bis-platinum complexes. Journal Of Inorganic Biochemistry 1989, 36: 160. DOI: 10.1016/0162-0134(89)84048-6.
• Prolymphocytic transformation of chronic lymphocytic leukemia: A case report of lengthy survival after intensive chemotherapyRoberts J, Tindle B, Macpherson B. Prolymphocytic transformation of chronic lymphocytic leukemia: A case report of lengthy survival after intensive chemotherapy. American Journal Of Hematology 1989, 31: 131-132. PMID: 2735318, DOI: 10.1002/ajh.2830310212.
• Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer.Colletti RB, Roberts JD, Devlin JT, Copeland KC. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Research 1989, 49: 1882-4. PMID: 2924327.
• Interaction of novel bis(platinum) complexes with DNARoberts J, Van Houten B, Qu Y, Farrell N. Interaction of novel bis(platinum) complexes with DNA. Nucleic Acids Research 1989, 17: 9719-9733. PMID: 2690006, PMCID: PMC335209, DOI: 10.1093/nar/17.23.9719.
• ChemInform Abstract: Water Soluble DACH‐Pt(II) Complexes: Problems of Purification; Stability of Complexes with Nitrogen‐Containing Ligands.ROBERTS J, SCHMIDT W, TONG W, HACKER M. ChemInform Abstract: Water Soluble DACH‐Pt(II) Complexes: Problems of Purification; Stability of Complexes with Nitrogen‐Containing Ligands. ChemInform 1988, 19: no-no. DOI: 10.1002/chin.198852282.
• Water soluble DACHPt(II) complexes: Problems of purification; Stability of complexes with nitrogen-containing ligandsRoberts J, Schmidt W, Tong W, Hacker M. Water soluble DACHPt(II) complexes: Problems of purification; Stability of complexes with nitrogen-containing ligands. Inorganica Chimica Acta 1988, 153: 123-127. DOI: 10.1016/s0020-1693(00)83870-0.
• Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.Stewart JA, McCormack JJ, Tong W, Low JB, Roberts JD, Blow A, Whitfield LR, Haugh LD, Grove WR, Lopez AJ. Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule. Cancer Research 1988, 48: 5029-35. PMID: 2970294.
• Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation.Roberts JD, Stewart JA, McCormack JJ, Krakoff IR, Culham CA, Hartshorn JN, Newman RA, Haugh LD, Young JA. Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation. Journal Of The National Cancer Institute 1987, 71: 141-9. PMID: 3802111.
• Metabolism of tiazofurin by human erythrocytes and mononuclear blood cells in vitroRoberts J, Tong W, Hartshorn J, Hacker M. Metabolism of tiazofurin by human erythrocytes and mononuclear blood cells in vitro. Cancer Letters 1986, 32: 193-197. PMID: 3756845, DOI: 10.1016/0304-3835(86)90119-9.
• Regional fibrosis after intraperitoneal administration of mafosfamideRoberts J, Newman R, Kimberly P, Hacker M. Regional fibrosis after intraperitoneal administration of mafosfamide. Investigational New Drugs 1986, 4: 61-65. PMID: 2939038, DOI: 10.1007/bf00172019.
• Low‐dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemiaRoberts JD, Ershler WB, Tindle BH, Stewart JA. Low‐dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia. Cancer 1985, 56: 1001-1005. PMID: 3860278, DOI: 10.1002/1097-0142(19850901)56:5<1001::aid-cncr2820560504>3.0.co;2-p.
• Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to miceRoberts J, Hacker M, Newman R, McCormack J, Krakoff I. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice. Investigational New Drugs 1984, 2: 215-220. PMID: 6469517, DOI: 10.1007/bf00232354.